Navigation Links
OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
Date:1/10/2008

NAPLES, Italy, Jan. 10 /PRNewswire/ -- Patients who received OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, had significantly fewer major cardiac adverse events (MACE) than patients who received Boston Scientific's TAXUS or Johnson & Johnson's CYPHER drug-eluting stents in a study conducted at Federico II University of Naples in Naples, Italy. The results of the study were presented recently at the XXVIII National Congress of the Italian Society of Invasive Cardiology by Federico Piscione, M.D., the study's principal investigator and a professor with the university's Division of Cardiology, Department of Clinical Medicine and Cardiovascular Sciences.

At clinical follow-up of 10 months, the cumulative MACE rate for the Genous group (GRS) was 4% versus 22% for the combined TAXUS and CYPHER group (DES). For the MACE components, the cumulative rate of target vessel revascularization (TVR) was 1% for GRS versus 11.8% for DES, the cumulative rate of myocardial infarction (MI) was 1% for GRS versus 7.8% for DES, and the cumulative mortality rate was 2% for GRS versus 7.8% for DES. In addition, the cumulative rate for stent thrombosis was 2% for GRS versus 5.8% for DES.

"Our findings suggest that the deployment of Genous stents in a consecutive series of high-risk patients is safe and effective, with a significantly lower in-hospital incidence of MACE and a better long-term clinical outcome when compared to drug-eluting stents," said Piscione. "Genous is a viable alternative to drug-eluting stents, which have raised many safety concerns among the interventional cardiology community. Unlike TAXUS and CYPHER that elute cytotoxic agents to inhibit neointimal proliferation, Genous attracts circulating endothelial progenitor cells to rapidly build a layer of healthy tissue and promote long-term natural healing."

The study involved 195 consecutive high-risk patients who underwent percutaneous coronary intervention (PCI) with either
'/>"/>

SOURCE Federico II University of Naples
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
6. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
7. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
8. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
9. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
10. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
11. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... cash dividend for the second quarter 2015 of $0.03 ... dividend of $0.03 per share will be paid on ... as of June 12, 2015.  The ex-dividend date for ...
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)... 21, 2015  Heidrick & Struggles (Nasdaq: HSII ... leadership consulting and culture shaping ... global practices announcing the addition of Tim Dietlin ... office. Dietlin has extensive life sciences ... across R&D, Medical and Commercial functions to increase productivity, ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Heidrick Increases Healthcare and Life Sciences Expertise 2
... (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical ... findings from analyses of pivotal trial,results of ... an,investigational once-daily medication, which is being evaluated ... Deficit Hyperactivity Disorder,(ADHD). The data demonstrated that ...
... Johnson & Johnson,will provide a pre-recorded webcast for ... (Eastern Time) to coincide with the American Pain ... clinical data presentations on,investigational tapentadol immediate release (IR), ... for the first time at APS., A ...
Cached Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce ... is now the 16th sweetFrog store located in the Lone ... #22 on the Inc. 500 list of fastest growing companies ... in East Texas for 20 years and love the natural ... Jacksonville, and nearby Palestine, sweetFrog locations. “We are really excited ...
(Date:5/22/2015)... AZ (PRWEB) May 22, 2015 In ... Olympics, Parker and Sons is offering to donate $5 ... installing an AC unit or water softening system. Customers ... behalf; Parker and Sons gets business; and the Special ... , The Special Olympics helps over 4.4 million athletes, ...
(Date:5/22/2015)... 22, 2015 Bryce Henson, local fitness ... Body Boot Camp, recently accepted his program’s 100th client. ... the launch of his location evidences the powerful impact ... , Fit Body Boot Camp is the nation’s most ... with hundreds of locations across North America, Europe and ...
(Date:5/22/2015)... May 22, 2015 Pro3rd Impression ... designed exclusively for Final Cut Pro X. Pro3rd Impression's ... design. , Intuitive on-screen-controls allow users to customize ... Reflections, colors, layouts, and much more can be edited ... , Pro3rd Impression comes packed with 30 ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 Absolute ... has a highly interactive, state-of-the-art website that is filled ... latest trade show resource information. With its original and ... well as practical. The website shows hundred of pictures ... trade show floor. This is not an exhibit rendering ...
Breaking Medicine News(10 mins):Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2Health News:New Convention and City Travel Guides Within the Absolute Exhibits’ Website 2
... to be unveiled at the 2008 Orthopedic Research ... Society meeting in San Francisco, ... collaboration with RUSH University in Chicago, announces significant,findings that wear ... accelerated aging. The study, "The Effect,of Accelerated Aging on the ...
... balance sheet and positions Company ... to focus on driving growth of EMR business, ... ("Nightingale" or the "Company") (TSX-V: NGH), one of North,America,s ... sale of its Therapist Helper business to Netsmart,Technologies Inc., ...
... 29 The office of,Congressman Walberg was recently ... huge cuts in Medicare that would significantly,limit health ... award from,The Coalition for Medicare Choices for his ... "The Medicare Advantage (MA) Program has offered ...
... life for patients , , FRIDAY, Feb. 29 (HealthDay News) ... take a break from chemotherapy, says a study by ... Institute. , The study included 250 men with metastatic, ... prostate and isn,t affected by the male hormone androgen. ...
... N.J., Feb. 29 Orchid Cellmark Inc.,(Nasdaq: ORCH ... will release its fourth quarter and full year 2007 ... am EST, and is,hosting a conference call and webcast ... same day. Management will discuss financial results for the,fourth ...
... what makes people susceptible to a common form of hearing ... that are of interest. In a study published in the ... the University of Washington have developed a research method that ... each side of a fish that enables it to sense ...
Cached Medicine News:Health News:Pioneer(R) Surgical Technology, Inc. Continues to Prove Science Behind PEEK-on-PEEK(TM) Technology for Motion Preservation Devices 2Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 2Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 3Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 4Health News:Chemo Break Benefits Some Men With Prostate Cancer 2Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 2Health News:Zebrafish provide useful screening tool for genes, drugs that protect against hearing loss 3
... Petri dish in 3 seconds. The counts ... the colonies as compared to those of ... three types of lighting: lower lighting for ... the agar and upper lighting for blood ...
Basic critical care testing. Measures pH, pCO2, and pO2 from 85 L whole-blood sample....
... The Rapidpoint 400 is a sophisticated ... specifically for point-of-care testing while also satisfying ... A single, multiple-use measurement cartridge contains all ... analyzer. This long-lasting cartridge includes the sampling ...
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
Medicine Products: